ArticleInfection and drug resistance2022
Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold - A Retrospective Cohort Study.
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- A Systematic Review of Population Pharmacokinetics, Safety, and Factors Influencing Trough Concentrations of Voriconazole in Asian Patients with Liver Dysfunction.Drug design, development and therapy · 2025Pooled it
- The dual role of azoles: lifesaving antifungals and drivers of resistance - a One Health perspective.Nature communications · 2026Review
- Trough concentration of voriconazole and its association with central nervous system toxicity in patients with hematologic malignancies: a retrospective cohort study.European journal of clinical pharmacology · 2026Article
- VALID regimen of voriconazole optimizes therapeutic target attainment and minimizes adverse events in patients with liver dysfunction.Frontiers in pharmacology · 2026Article
- Voriconazole-associated adverse drug reactions in Chinese patients: incidence, clinical features and the predictive value of ALBI score for hepatotoxicity.Frontiers in pharmacology · 2026Article
- Voriconazole-induced Hypoglycemia in a Non-diabetic Patient: A Rare Cause.Clinical medicine & research · 2025Article
- Pharmacological Management of Oral and Esophageal Candidiasis: A Clinical Pharmacotherapy Perspective.Journal of clinical medicine · 2025Review
- Contemporary review of critical illness following allogeneic hematopoietic stem cell transplant in adults.Intensive care medicine · 2025Review
- Voriconazole-associated liver injury: clinical risk factor identification and predictive nomogram construction.Frontiers in pharmacology · 2025Article
- Study on the correlation between plasma concentration of voriconazole and clinical efficacy and safety in elderly patients.Frontiers in pharmacology · 2025Article
- INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities.Transplantation and cellular therapy · 2024Review
- The impact of gene polymorphism and hepatic insufficiency on voriconazole dose adjustment in invasive fungal infection individuals.Frontiers in genetics · 2023Review
- Update on therapeutic approaches for invasive fungal infections in adults.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Voriconazole (VRC) is an antifungal agent which is used for treatment and prophylaxis of invasive fungal infections. The common clinical adverse reactions mainly include central nervous system (CNS) toxicity and abnormal liver function. These adverse reactions limit the clinical use of voriconazole to a certain extent. Therefore, the aim of this study was to analyze the risk factors of voriconazole neurotoxic side effects and to determine the plasma trough concentration ( Patients and Methods: This study retrospectively collected the clinical data of 165 patients who received voriconazole and underwent therapeutic drug monitoring (TDM). CNS toxicity was defined using the National Cancer Institute (NCI) criteria, logistic regression was used to analyze the risk factors of CNS toxicity, classification and Regression tree (CART) model was used to determine the Results: Voriconazole-related CNS toxicity occurred during treatment in 34 of 165 patients (20.6%) and the median time from administration to onset of CNS toxicity was 6 days (range, 2-19 days). The overall incidence of CNS toxicity was 20.6% (34/165), including visual disturbances in 4.8% (8/165) and nervous system disorders in 15.8% (26/165). Conclusion: Voriconazole trough concentration of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.